Target Group Inc. (OTCQB: CBDY)
is pleased to announce that its wholly owned subsidiary, Canary Rx Inc. ( Canary or the Company ) has completed its first three (3) B2B wholesale cannabis transactions through its strategic joint-venture, Venn Cannabis, marking the beginning of a promising future for the company.
Canary RX, through its joint venture partnership, Venn Cannabis, has been working meticulously to ensure production of ultra-premium, craft cannabis in its Simcoe, Ontario production facility, enabling delivery of its unique genetic offerings and providing a strong platform for other retail brands in the market to build a portfolio of whole flower consumer products. The company is currently in discussions with several additional licenced producers and is very optimistic that over the next year, can establish itself as a leader in contract-based craft cultivation at scale within the Canadian cannabis landscape.